ATXI

100.00% -0.735

Handel nachbörslich: .29 0.29 +

Avenue Therapeutics Inc (ATXI)

Überblick Nachrichten Preisverlauf Financials Warum fällt ATXI? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Avenue Therapeutics Inc Stock (ATXI) Company Profile

Avenue Therapeutics Inc

Healthcare (1112)

Biotechnology (620)

Nächster Verdiensttermin

Neueste SEC-Einreichungen

ATXI's Discussions on Twitter

Compare ATXI vs VRTX, REGN, ARGX, ALNY, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ATXI Avenue Therapeutics Inc	0.00	0	1.40M	-3.78M	-1.74M	-1.4649
VRTX Vertex Pharmaceuticals Inc	433.07	115.27B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	737.71	80.00B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	691.40	43.00B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	317.36	43.52B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	283.03	30.74B	5.36B	287.73M	924.18M	2.5229

Avenue Therapeutics Inc Aktie (ATXI) Neueste Nachrichten

Finanzdaten der Avenue Therapeutics Inc-Aktie (ATXI)

Avenue Therapeutics Inc (ATXI)

Avenue Therapeutics Inc Stock (ATXI) Company Profile

Compare ATXI vs VRTX, REGN, ARGX, ALNY, ONC

Avenue Therapeutics Inc Aktie (ATXI) Neueste Nachrichten

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $403 Million - The Manila Times

Turn Therapeutics secures up to $25M in financing from Avenue Capital Group - msn.com

Turn Therapeutics Secures Up to $25 Million Financing from Avenue Capital to Advance Atopic Dermatitis and Onychomycosis Programs - Minichart

Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group - PharmiWeb.com

Turn Therapeutics Secures Up To $25 Million Term Loan Facility From Avenue Venture Opportunities - TradingView

Turn Therapeutics (Nasdaq: TTRX) secures up to $25M loan facility - Stock Titan

Turn Therapeutics secures $25M loan facility from Avenue Capital - investing.com

Turn Therapeutics, Inc. Secures Up to $25 Million in Financing from Avenue Capital Group - marketscreener.com

Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering - Sahm

Turn Therapeutics Inc. announced that it expects to receive $25 million in funding from Avenue Capital Management II, L.P. - marketscreener.com

Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering - Sahm

Fortress Biotech (FBIO) Executive Vice Chairman granted 475,424 restricted shares - Stock Titan

Neurology stocks rebound in 2025 after midyear slump - BioWorld MedTech

TG Therapeutics, Inc.Common Stock (NQ: TGTX - The Chronicle-Journal

Tangible book value per share of Avenue Therapeutics, Inc. – LS:A40BWJ - TradingView

Net current asset value per share of Avenue Therapeutics, Inc. – LS:A40BWJ - TradingView

Viridian Therapeutics (NASDAQ:VRDN) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat

Deal Watch: Esperion Augments Cardiovascular Franchise Via Corstasis Buyout - Citeline News & Insights

Halozyme Therapeutics, Inc. $HALO Shares Sold by Cary Street Partners Financial LLC - MarketBeat

Edgewise Therapeutics (NASDAQ:EWTX) Downgraded to Sell Rating by Wall Street Zen - MarketBeat

ATXI Stock News Today | Earnings, Events & Price Alerts - Intellectia AI

Avenue Therapeutics to develop add-on Pompe disease treatment - Pompe Disease News

Avenue Therapeutics Licenses ATX-04 for Pompe Disease - The Globe and Mail

Avenue Therapeutics licenses ATX-04 for Pompe disease treatment By Investing.com - Investing.com Australia

Avenue Therapeutics (OTC: ATXI) licenses ATX-04 Pompe therapy from Duke - Stock Titan

Avenue Therapeutics licenses ATX-04 for Pompe disease treatment - Investing.com

After Menkes drug approval, Fortress moves to cash in $205M voucher - Stock Titan

Avenue Therapeutics Enters into Exclusive Worldwide License - GlobeNewswire

Rare muscle disease drug deal: Avenue backs ATX-04 for Pompe - Stock Titan

Lion Street Advisors LLC Buys 5,619 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat

Halozyme Therapeutics (NASDAQ:HALO) Downgraded to Hold Rating by Wall Street Zen - MarketBeat

Candel Therapeutics Announces Pricing of Public Offering - The Manila Times

Ikarian Capital discloses 4.1% Avenue Therapeutics (ATXI) stake in 13G/A - Stock Titan

Context Therapeutics (NASDAQ:CNTX) Upgraded to Hold at Wall Street Zen - MarketBeat

Contineum Therapeutics (NASDAQ:CTNM) Rating Increased to Hold at Wall Street Zen - MarketBeat

Wall Street Zen Downgrades Kyverna Therapeutics (NASDAQ:KYTX) to Sell - MarketBeat

Warrant approval could dilute Dogwood Therapeutics (NASDAQ: DWTX) holders - Stock Titan

Cullinan Therapeutics (NASDAQ:CGEM) Rating Lowered to Sell at Wall Street Zen - MarketBeat

Edgewise Therapeutics (NASDAQ:EWTX) Downgraded by Wall Street Zen to Sell - MarketBeat

Maze Therapeutics (NASDAQ:MAZE) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat

VIVOS Therapeutics, Inc. ($VVOS) Signs 12-Part Media Series with New to The Street - The Joplin Globe

Axsome Therapeutics says AXS-12 NDA submission on track for January - MSN

Century Therapeutics (NASDAQ:IPSC) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat

Aquestive Therapeutics (NASDAQ:AQST) Lowered to Sell Rating by Wall Street Zen - MarketBeat

Cullinan Therapeutics (NASDAQ:CGEM) Upgraded by Wall Street Zen to Hold Rating - MarketBeat

Esperion Therapeutics (NASDAQ:ESPR) Raised to "Buy" at Wall Street Zen - MarketBeat

TMC the metals (NASDAQ:TMC) vs. Canadian Zeolite (OTCMKTS:IZCFF) Critical Review - Defense World

Analyzing Turn Therapeutics (TTRX) & The Competition - Defense World

HCA Healthcare (NYSE:HCA) Shares Gap Up After Earnings Beat - Defense World

Boku (LON:BOKU) Insider Jonathan Peter Prideaux Sells 325,000 Shares of Stock - Defense World

Anchor Line Partners Supports Stoke Therapeutics' Growth by Securing a 98,500 Square-Foot Lease in Waltham, MA - Morningstar

Finanzdaten der Avenue Therapeutics Inc-Aktie (ATXI)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie ATXI